glp 1 with dpp 4 DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits Mechanism of action for GIP,

In the SURMOUNT-1 trial, the highest dose of Tirzepatide produced an average weight loss of 22.5% over 72 weeks the largest seen with any approved weight loss medication in Canada

6 Multi-agonist strategies are increasingly being studied, some of which include dual GLP-1/GIP agonists like tirzepatide and triple agonists that target GLP-1, GIP, and glucagon-like retatrutide

It is not Ozempic, Wegovy, Mounjaro, Zepbound or a generic version of those medications

designation)

This comprehensive evidence-based Guideline is constructed from a rigorous, Appraisal of Guidelines for Research and Evaluation-II (AGREEII)-compliant, evidence-based guideline development process